Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Talquetamab vs Daratumumab and Lenalidomide in MRD-Positive Multiple Myeloma After ASCT
NCT07740486Phase 3Not yet recruiting
- Sponsor
- Polish Myeloma Consortium
- Start
- Sep 2026
- Primary completion
- Jun 2031
01
Overview
Phase 3, randomised, open-label trial of teclistamab and talquetamab in multiple myeloma (MM) (2 arms), sponsored by Polish Myeloma Consortium. Primary endpoint: Proportion of Participants Achieving MRD Negativity With Complete Response at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07740486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07740486.